A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Uncommon EGFR Mutations Only)

NCT06010329 Phase 2 RECRUITING

The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).

Details

Lead sponsor	Teligene US
Phase	Phase 2
Status	RECRUITING
Enrolment	66
Start date	2023-12-27
Completion	2028-12

Conditions

• Non-small Cell Lung Cancer

Interventions

• Sutetinib Maleate Capsule

Primary outcomes

• Objective Response Rate (ORR) — Pre-dose up to approximately 32 months post-dose

Countries

United States